

Cite this article as: Barili F, Freemantle N, Folliguet T, Muneretto C, De Bonis M, Czerny M *et al.* The flaws in the detail of an observational study on transcatheter aortic valve implantation versus surgical aortic valve replacement in intermediate-risks patients. *Eur J Cardiothorac Surg* 2017;51:1031–5.

## The flaws in the detail of an observational study on transcatheter aortic valve implantation versus surgical aortic valve replacement in intermediate-risks patients<sup>†</sup>

Fabio Barili<sup>a,\*</sup>, Nick Freemantle<sup>b,†</sup>, Thierry Folliguet<sup>c</sup>, Claudio Muneretto<sup>d</sup>, Michele De Bonis<sup>e</sup>, Martin Czerny<sup>f</sup>, Jean Francois Obadia<sup>g</sup>, Nawwar Al-Attar<sup>h</sup>, Nikolaos Bonaros<sup>i</sup>, Jolanda Kluijn<sup>j</sup>, Roberto Lorusso<sup>k</sup>, Prakash Punjabi<sup>l</sup>, Rafael Sadaba<sup>m</sup>, Piotr Suwalski<sup>n,o</sup>, Umberto Benedetto<sup>p</sup>, Andreas Böning<sup>q</sup>, Volkmar Falk<sup>r</sup>, Miguel Sousa-Uva<sup>s</sup>, Pieter A. Kappetein<sup>t</sup> and Lorenzo Menicanti<sup>u</sup>

<sup>a</sup> Department of Cardiac Surgery, S. Croce Hospital, Cuneo, Italy

<sup>b</sup> Department of Primary Care and Population Health, University College London, London, UK

<sup>c</sup> Department of Cardiac Surgery, Centre Hospitalo-Universitaire Brabois ILCV, Nancy, France

<sup>d</sup> Department of Cardio-Thoracic Surgery, University of Brescia-Spedali Civili, Brescia, Italy

<sup>e</sup> Department of Cardiac Surgery, S. Raffaele University Hospital, Milan, Italy

<sup>f</sup> Department of Cardiovascular Surgery, University Heart Center Freiburg- Bad Krozingen, Germany

<sup>g</sup> Department of Cardio-Thoracic Surgery, Hopital Cardiothoracique Louis Pradel, Lyon, France

<sup>h</sup> Department of Cardiac Surgery, Golden Jubilee National Hospital, Glasgow, UK

<sup>i</sup> Department of Cardiac Surgery, Innsbruck Medical University, Innsbruck, Austria

<sup>j</sup> Department of Cardio-Thoracic Surgery, AMC, Amsterdam, Netherlands

<sup>k</sup> Department of Cardio-Thoracic Surgery, Heart and Vascular Centre-Maastricht University Medical Centre, Maastricht, Netherlands

<sup>l</sup> Department of Cardio-Thoracic Surgery, Imperial College Healthcare NHS Trust and Imperial College School of Medicine, London, UK

<sup>m</sup> Department of Cardiac Surgery, Complejo Hospitalario de Navarra - NavarraBiomed. Pamplona, Spain

<sup>n</sup> Department of Cardiac Surgery, Central Clinical Hospital of the Ministry of the Interior, Warsaw, Poland

<sup>o</sup> Pulaski University of Technology and Humanities, Radom, Poland

<sup>p</sup> Bristol Heart Institute, University of Bristol, School of Clinical Sciences, Bristol, UK

<sup>q</sup> Department of Cardio-Vascular Surgery, University Hospital Giessen, Giessen, Germany

<sup>r</sup> Department of Cardio-Thoracic Surgery, Deutsches Herzzentrum Berlin, Charite Berlin, Germany

<sup>s</sup> Department of Cardiac Surgery, Hospital Cruz Vermelha, Lisbon, and Faculdade de Medicina da Universidade do Porto, Portugal

<sup>t</sup> Thoraxcenter, Erasmus MC, Rotterdam, Netherlands

<sup>u</sup> Department of Cardiac Surgery, IRCCS Policlinico S. Donato, Milan, Italy

\* Corresponding author. Department of Cardiac Surgery, S. Croce Hospital, Via M. Coppino 26, 12100 Cuneo, Italy. Tel: +39-01-71642571; fax: +39-01-71642064; e-mail: fabarili@libero.it; barili.f@ospedale.cuneo.it (F. Barili).

Received 13 December 2016; received in revised form 25 January 2017; accepted 7 February 2017

### Abstract

The PARTNER group recently published a comparison between the latest generation SAPIEN 3 transcatheter aortic valve implantation (TAVI) system (Edwards Lifesciences, Irvine, CA, USA) and surgical aortic valve replacement (SAVR) in intermediate-risk patients, apparently demonstrating superiority of the TAVI and suggesting that TAVI might be the preferred treatment method in this risk class of patients. Nonetheless, assessment of the non-randomized methodology used in this comparison reveals challenges that should be addressed in order to elucidate the validity of the results. The study by Thourani and colleagues showed several major methodological concerns: sub-optimal methods in propensity score analysis with evident misspecification of the propensity scores (PS; no adjustment for the most significantly different covariates: left ventricular ejection fraction, moderate-severe mitral regurgitation and associated procedures); use of PS quintiles rather than matching; inference on not-adjusted Kaplan-Meier curves, although the authors correctly claimed for the need of balancing score adjusting for confounding factors in order to have unbiased estimates of the treatment effect; evidence of poor fit; lack of data on valve-related death.

These methodological flaws invalidate direct comparison between treatments and cannot support authors' conclusions that TAVI with SAPIEN 3 in intermediate-risk patients is superior to surgery and might be the preferred treatment alternative to surgery.

**Keywords:** Transcatheter valve therapy • Valve disease • Aortic valve replacement • Propensity score analysis • Statistical analysis

<sup>†</sup>Presented at the Postgraduate Course of the 30th Annual Meeting of the European Association for Cardio-Thoracic Surgery, Barcelona, Spain, 2 October 2016.

<sup>†</sup>The first two authors contributed equally to this study.

## GENERAL CONSIDERATION

The development and availability of a transcatheter approach for treating severe aortic valve stenosis [transcatheter aortic valve implantation (TAVI)] has warranted clinical trials and observational studies to evaluate the safety and short-/long-term outcomes of newly designed prostheses in order to compare them with surgical aortic valve replacement (SAVR), the gold standard treatment [1, 2]. The new treatment has been initially reserved for patients with absolute contraindications to surgery. Subsequently, the evidence of safety of the new devices, as well as the maturation of experience with this technology, has led to the expansion of indications to higher risk patients [3, 4]. Nonetheless, technology runs fast, and new prostheses are regularly launched on the market claiming better performances and wider indications and hence requiring new evidence [5]. The PARTNER group recently published a comparison between the latest generation SAPIEN 3 TAVI system (Edwards Lifesciences, Irvine, CA, USA) and SAVR in intermediate-risk patients, apparently demonstrating superiority of the TAVI and suggesting that TAVI might be the preferred treatment method in this risk class of patients [6]. These favourable results of transcatheter approach in intermediate risk-patients could lead the decision-makers and the scientific community to consider TAVI as the new standard of care in a wider population of patients with severe aortic stenosis. The recent Food and Drug Administration (FDA) approval for expanded indications for SAPIEN 3 device based on their data somewhat support this position ([http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm517281.htm?source=govdelivery&utm\\_medium=email&utm\\_source=govdelivery](http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm517281.htm?source=govdelivery&utm_medium=email&utm_source=govdelivery)).

Nonetheless, assessment of the non-randomized methodology used in this comparison reveals challenges that should be addressed in order to elucidate the validity of the results. The study is observational, employing propensity scores (PS), risk scores that can be used to match patients with a similar likelihood of receiving treatment, since non-random differences in baseline will lead to bias in comparisons between treatment conditions [7–9]. PS analysis can be used to create a ‘quasi-randomized’ comparison, but the approach has well-known intrinsic limitations and pitfalls including the misspecification of the PS, effects of unknown biases and confounding by indication [9–13]. Hence, unlike properly randomized trials, the use of the PS does not assure the internal validity of the analyses, and decision-makers and the scientific communities need to be wary of making inference from their results [11]. The PS study by Thourani *et al.* has a number of major design flaws, and its results have clear signs of bias [6].


## THE ASSUMPTION OF ‘IGNORABILITY’ AND THE EFFECTS OF PROPENSITY SCORE MISSPECIFICATION

The first important step in PS analysis is the careful specification of the risk algorithm, as omission of important confounding factors (e.g. getting it wrong) will lead to biased estimation of treatment effect. The objective is that as a result of the PS conditioning of the relevant explanatory variables, the treatment will be independent of potential outcomes. This conditional independence assumption is called ‘ignorability’, ‘unconfoundedness’, ‘selection on observables’ and crucially it is always held as an assumption, because it is not directly testable [14]. In order to

assume that treatment assignment is ‘otherwise ignorable’ [9–15], the very first step is the inclusion in the PS algorithm of all known and available confounding factors, as explanatory variables that meet the condition of affecting both treatment assignment and outcome confound the observed relationship between treatment and outcome [9–15]. The PS is compromised when important variables influencing selection have not been collected or considered and misspecification of the PS by excluding known confounders has been demonstrated to lead to largely biased results [10].

The study by Thourani *et al.* was designed to compare the outcomes of an observational study on the latest generation SAPIEN 3 TAVI System (Edwards Lifesciences, Irvine, CA, USA) with results of the surgical group of the PARTNER 2A trial [5, 6, 16]. The 2 groups were not homogeneous, as shown in baseline characteristics and Thourani *et al.* planned PS stratification before analysing outcomes [6]. The use of PS stratification rather than precise matching is surprising, as it is by design limited in the extent to which systematic differences between the comparator groups may be accounted for. Indeed, there were important differences between the comparator samples. The comparative analysis of patients’ baseline characteristics and baseline variables included in the PS algorithm showed that the most significantly different characteristics between the 2 groups (left ventricular ejection fraction,  $P$ -value <0.0001; society of thoracic surgeons (STS) score,  $P$ -value 0.0002; moderate or severe mitral regurgitation,  $P$ -value <0.0001) were omitted in the PS generation, together with other significant factors (frail condition and mean gradient). STS score has been developed to estimate early mortality, and it was demonstrated to be also a predictor of long-term mortality [17–20]. Several studies and meta-analyses demonstrated that both left ventricular ejection fraction and moderate/severe mitral regurgitation affect early and late outcomes, also in patients who undergo TAVI [21–24]. These factors, affecting both treatment assignment and outcomes, are hence major confounders that should be included in the PS. Their omission may violate the ‘ignorability’ assumption and, consequently, may lead to selection bias.

Moreover, further potential confounders not collected in the study are associated procedures, such as myocardial revascularization. These increase the risk of perioperative mortality and morbidity as widely demonstrated by STS score and EuroSCORE [17–27], and they could represent important confounders to be included in the PS algorithm. Nonetheless, although patients with non-complex coronary disease requiring revascularization were included whether a treatment plan for the coronary disease was agreed before enrolment [5, 6, 16], no information on associated myocardial revascularization in the TAVI group has been reported [6, 16]. Some information on the SAVR group can be derived from the published PARTNER 2A trial, where a total of 86 of 944 patients (9.1%) had concomitant procedures during surgery and 137 of 944 patients (14.5%) underwent associated coronary artery bypass grafting [5]. Thus, a proportion ranging between 14.5% and 23.6% had concomitant surgical procedures in the SAVR group of the PARTNER 2A trial, indicating an increased risk of mortality and morbidity and potentially a major confounder. The need for a deeper analysis on associated procedures in the Thourani *et al.*’s study is also strengthened by the significantly different proportion of myocardial revascularization in the PARTNER 2A trial (137 of 994, 14.5% in the SAVR; 39 of 994, 3.9% in the TAVI group;  $\chi^2$   $P$ -value <0.0001) [5].



**Figure 1:** Treatment effect of TAVR versus surgery on all-cause mortality and stroke in PARTNER 2A randomized trial and PARTNER 2A SAPIEN 3 observational study.

In summary, these differences in baseline characteristics between study groups reflect a different clinical selection of patients that can influence outcomes and should be balanced to avoid biased estimation of treatment effect.

### CONFOUNDING BY INDICATION AND ASSESSING THE PERFORMANCE OF THE PROPENSITY SCORE

Confounding by indication is the situation where, although all known confounders have been balanced, allocation to treatment is not otherwise ignorable but instead subject to some latent (unrecognized or unmeasured) process associated with those who are treated. This confounding cannot be measured directly but only tangentially through its effects and hence the effort should be focused on performance analysis of PS [11].

The first useful precaution against unsafe inference from an observational study is to compare it with a known treatment effect and bridge from that point to consider further questions. A deeper step in diagnostic should be the evaluation of PS performance through testing the potential heterogeneity of the treatment effect across the range of the PS. A comparison between 2 well-balanced groups should lead to a homogeneous treatment effect across the range of the PS, while heterogeneous effects will raise concern.


The treatment effect of the observational study by Thourani *et al.* [6] can be compared with the PARTNER 2A randomized trial [5]. As shown in Fig. 1, the relative risk of the main outcome (all-cause death or disabling stroke) significantly differs from the 2 studies (interaction  $P$ -value = 0.0001), which militates against drawing strong conclusions in the observational study. Moreover, a deeper analysis of the treatment effect across the PS quintiles shows that the treatment effect may not be homogeneous across classes, showing a decreasing pattern through strata (Fig. 2). Only the treatment effect in the fifth quintile is similar to the PARTNER 2A trial effect. It can be hypothesized that in patients with low likelihood of TAVI (lower quintiles of PS) there is important information that the PS did not capture and so the match was made with inappropriately low-risk individuals, leading to a not otherwise ignorable treatment assignment [11].

### TO ADJUST OR NOT TO ADJUST, THIS IS ANOTHER QUESTION

The concerns also increase in the second part of the study, the time-to-event analyses. The study is based on the evidence that groups are different and biased estimated of treatment effects need to be accounted for by balancing the covariates with PS methods [6]. Nonetheless, after employing PS stratification for comparing dichotomic outcomes, the authors surprisingly did not undertake any type of adjustment in time-to-event analysis and presented simple unadjusted Kaplan-Meier estimates and curves, making inference on their results [6]. This is counter-intuitive and the curves are not interpretable, as they are simply a first-step evaluation before adjustment. Stating in results 'important differences between TAVR and surgery for each end-point are observed in the first several months' is inappropriate until results are confirmed by adjusted results. Making inference on unadjusted outcomes derived from biased groups should be avoided [9, 13].

### IS THERE AN OUTCOME MISSING?

In the PARTNER 2 SAPIEN 3 observation study, clinical outcomes were reported as defined by Valve Academic Research Consortium 2 definitions [6, 28]. The Valve Academic Research Consortium 2 definitions recommend capturing the cause of death with a careful review and, among mortality causes to be reported, all valve-related deaths are included. Valve-related mortality and morbidity represent the main outcomes to evaluate the safety and short-/long-term follow-up after valvular treatment, as it is the most specific index of early-late performance. In a comparison, between 2 treatment options for valvular disease considering two homogeneous groups, we might reasonably expect to observe a similar non-cardiovascular and cardiac non-valve-related mortality, while the treatment effect would be expressed in differences in valve-related mortality [29]. Nonetheless, in the PARTNER 2 SAPIEN 3 observation study, only all-cause mortality, non-cardiac and cardiac death were reported, with no information on valve-related mortality shown. Therefore, as it is not possible to differentiate



**Figure 2:** Treatment effect of TAVR versus surgery on composite outcome (death, stroke and moderate or severe aortic regurgitation at 1 year) across the quintiles of propensity score in the PARTNER 2A SAPIEN 3 observational study.

prostheses-related events from prostheses-unrelated deaths, such as these caused by non-embolic myocardial infarction, defined as cardiac but non-valve-related death [28, 29].

## CONCLUSIONS

As shown, the study on the comparison between SAPIEN 3 TAVR and surgical AVR [6] has demonstrated several major methodological concerns:

- suboptimal methods in PS analysis with evident misspecification of the PS (no adjustment for the most significantly different covariates: left ventricular ejection fraction, moderate-severe mitral regurgitation and associated procedures);
- use of PS quintiles rather than matching;
- inference on not-adjusted Kaplan-Meier curves, although the authors correctly claimed for the need of balancing score for adjusting for confounding factors in order to have unbiased estimates of the treatment effect;
- evidence of poor fit; and
- lack of data on valve-related death.

These methodological flaws invalidate direct comparison between treatments and cannot support authors' conclusions that TAVI with SAPIEN 3 in intermediate-risk patients is superior to surgery and might be the preferred treatment alternative to surgery.

**Conflict of interest:** F.B. reports personal fees from St Jude Medical, outside the submitted work. N.B. reports research grant from Edwards Lifescience and speaker's honoraria from Edwards Lifescience, Medtronic and Abbott (outside the submitted work). R.L. is the principal investigator of the PERSIST-AVR Trial. P.S. is a consultant for Atricure and Medtronic (outside the submitted work).

## REFERENCES

- [1] Vahanian A, Alfieri O, Andreotti F, Antunes MJ, Barón-Esquivias G, Baumgartner H *et al.* Guidelines on the management of valvular heart disease (version 2012): the Joint Task Force on the Management of Valvular Heart Disease of the European Society of Cardiology (ESC) and the European Association for Cardio-Thoracic Surgery (EACTS). *Eur J Cardiothorac Surg* 2012;42:S1–44.
- [2] Nishimura RA, Otto CM, Bonow RO, Carabello BA, Erwin JP 3rd, Guyton RA *et al.* 2014 AHA/ACC guideline for the management of patients with valvular heart disease: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. *J Thorac Cardiovasc Surg* 2014;148:e1–132.
- [3] Mack MJ, Leon MB, Smith CR, Miller DC, Moses JW, Tuzcu EM *et al.* 5-year outcomes of transcatheter aortic valve replacement or surgical aortic valve replacement for high surgical risk patients with aortic stenosis (PARTNER 1): a randomised controlled trial. *Lancet* 2015;385:2477–84.
- [4] Kapadia SR, Leon MB, Makkar RR, Tuzcu EM, Svensson LG, Kodali S *et al.* 5-year outcomes of transcatheter aortic valve replacement compared with standard treatment for patients with inoperable aortic stenosis (PARTNER 1): a randomised controlled trial. *Lancet* 2015;385:2485–91.
- [5] Leon MB, Smith CR, Mack MJ, Makkar RR, Svensson LG, Kodali SK *et al.* Transcatheter or surgical aortic-valve replacement in intermediate-risk patients. *N Engl J Med* 2016;374:1609–20.
- [6] Thourani VH, Kodali S, Makkar RR, Herrmann HC, Williams M, Babaliaros V *et al.* Transcatheter aortic valve replacement versus surgical valve replacement in intermediate-risk patients: a propensity score analysis. *Lancet* 2016;387:2218–25.
- [7] Rosenbaum PR, Dubin DB. The central role of the propensity score in observational studies for causal effect. *Biometrika* 1983;70:41–55.
- [8] Rosenbaum PR, Dubin DB. Reducing bias in observational studies using subclassification on the propensity score. *J Am Stat Assoc* 1984;79:516–24.
- [9] Blackstone E. Comparing apples and oranges. *J Thorac Cardiovasc Surg* 2002;123:8–15.
- [10] Drake C. Effects of misspecification of the propensity score on estimators of treatment effects. *Biometrics* 1993;49:1231–36.
- [11] Freemantle N, Marston L, Walters K, Wood J, Reynolds MR, Petersen I. Making inferences on treatment effects from real world data: propensity scores, confounding by indication, and other perils for the unwary in observational research. *BMJ* 2013;347:f6409.



- [12] Rosenbaum PR. Optimal matching for observational studies. *J Am Stat Assoc* 1989;84:1024–32.
- [13] D'Agostino RB Jr. Propensity score methods for bias reduction in the comparison of a treatment to a non-randomized control group. *Stat Med* 1998;17:2265–81.
- [14] Xie Y, Brand JE, Jann B. Estimating heterogeneous treatment effects with observational data. *Sociol Methodol* 2012;42:314–47.
- [15] Rubin DB. Estimating causal effects from large data sets using propensity scores. *Ann Intern Med* 1997;127:757–63.
- [16] Kodali S, Thourani VH, White J, Malaisrie SC, Lim S, Greason KL *et al.* Early clinical and echocardiographic outcomes after SAPIEN 3 transcatheter aortic valve replacement in inoperable, high-risk and intermediate-risk patients with aortic stenosis. *Eur Heart J* 2016;37:2252–62.
- [17] O'Brien SM, Shahian DM, Filardo G, Ferraris VA, Haan CK, Rich JB *et al.* The Society of Thoracic Surgeons 2008 cardiac surgery risk models: part 2—isolated valve surgery. *Ann Thorac Surg* 2009;88(Suppl 1):S23–42.
- [18] Shahian DM, He X, Jacobs JP, Rankin JS, Welke KF, Filardo G *et al.* The society of thoracic surgeons isolated aortic valve replacement (AVR) composite score: a report of the STS quality measurement task force. *Ann Thorac Surg* 2012;94:2166–71.
- [19] Barili F, Pacini D, D'Ovidio M, Ventura M, Alamanni F, Di Bartolomeo R *et al.* Reliability of modern scores to predict long-term mortality after isolated aortic valve operations. *Ann Thorac Surg* 2016;101:599–605.
- [20] Barili F, Pacini D, Capo A, Ardemagni E, Pellicciari G, Zanobini M *et al.* Reliability of new scores in predicting perioperative mortality after isolated aortic valve surgery: a comparison with the society of thoracic surgeons score and logistic EuroSCORE. *Ann Thorac Surg* 2013;95:1539–44.
- [21] Eleid MF, Goel K, Murad MH, Erwin PJ, Suri RM, Greason KL *et al.* Meta-analysis of the prognostic impact of stroke volume, gradient, and ejection fraction after transcatheter aortic valve implantation. *Am J Cardiol* 2015;116:989–94.
- [22] Sannino A, Losi MA, Schiattarella GG, Gargiulo G, Perrino C, Stabile E *et al.* Meta-analysis of mortality outcomes and mitral regurgitation evolution in 4,839 patients having transcatheter aortic valve implantation for severe aortic stenosis. *Am J Cardiol* 2014;114:875–82.
- [23] Schubert SA, Yarburo LT, Madala S, Ayunipudi K, Kron IL, Kern JA *et al.* Natural history of coexistent mitral regurgitation after aortic valve replacement. *J Thorac Cardiovasc Surg* 2016;151:1032–9.
- [24] Tan TC, Flynn AW, Chen-Tournoux A, Rudski LG, Mehrotra P, Nunes MC *et al.* Risk prediction in aortic valve replacement: incremental value of the preoperative echocardiogram. *J Am Heart Assoc* 2015;4:e002129.
- [25] Shahian DM, O'Brien SM, Filardo G, Ferraris VA, Haan CK, Rich JB *et al.* The Society of Thoracic Surgeons 2008 cardiac surgery risk models: part 3—valve plus coronary artery bypass grafting surgery. *Ann Thorac Surg* 2009;88(Suppl 1):S43–62.
- [26] Nashef SA, Roques F, Sharples LD, Nilsson J, Smith C, Goldstone AR *et al.* EuroSCORE II. *Eur J Cardiothorac Surg* 2012;41:734–44.
- [27] Barili F, Pacini D, Capo A, Rasovic O, Grossi C, Alamanni F *et al.* Does EuroSCORE II perform better than its original versions? A multicentre validation study. *Eur Heart J* 2013;34:22–9.
- [28] Kappetein AP, Head SJ, G en ereux P, Piazza N, van Mieghem NM, Blackstone EH *et al.* Updated standardized endpoint definitions for transcatheter aortic valve implantation: the Valve Academic Research Consortium-2 consensus document. *Eur J Cardiothorac Surg* 2012;42:S45–60.
- [29] Akins CW, Miller DC, Turina MI, Kouchoukos NT, Blackstone EH, Grunkemeier GL *et al.* Guidelines for reporting mortality and morbidity after cardiac valve interventions. *J Thorac Cardiovasc Surg* 2008;135:732–8.

European Journal of Cardio-Thoracic Surgery 51 (2017) 1035–1036  
doi:10.1093/ejcts/ezx140

## EDITORIAL COMMENT

Cite this article as: Diegeler A. The truth is hidden in the details - Comment on an observational study on transcatheter aortic valve implantation versus surgical aortic valve replacement in intermediate-risks patients. *Eur J Cardiothorac Surg* 2017;51:1035–6.

# The truth is hidden in the details - Comment on an observational study on transcatheter aortic valve implantation versus surgical aortic valve replacement in intermediate-risks patients

Anno Diegeler\*

Herz- und Gef a sklinik Bad Neustadt, Klinik f ur Kardiochirurgie, Bad Neustadt a.d. Saale, Germany

\* Corresponding author. Herz- und Gef a sklinik Bad Neustadt, Klinik f ur Kardiochirurgie, Salzburger Leite 1, 97616 Bad Neustadt a.d. Saale, Germany. Tel: +49-9771-662416; fax: +49-9771-65989218; e-mail: a.diegeler@herzchirurgie.de (A. Diegeler).

**Keywords:** Adult cardiac surgery • Aortic valve disease • aortic valve replacement • Transcatheter valve replacement

The comparison of different therapeutic options for the treatment of a major disease is a significant scientific task, especially when it concerns reducing risks for patients. In general, everyone would agree that an innovative therapy, which leads to the same results but offers a demonstrably lower risk, must completely replace the conventional one. In the field of medicine, this is by all means possible but not so often the case. Instead, conventional therapies are further developed, and less risky variations of these established therapies can be offered, which can lead to the same results under particular best-case scenarios. In these cases, it is not the question

of which therapy is the best one; rather, it is a question of which patient is an ideal candidate for a particular therapy.

In today's world of a complete economization, there is the trend and the temptation: The winner takes it all... and demands it. If one were to go against the trend and try to search for the best possible method for the individual patient, different scientific questions would be asked, and different statistical methods would be chosen over the oft-used current ones, a carefully selected patient cohort and a 'non-inferiority' analysis.